Fabry disease: Clinical spectrum and evidence-based enzyme replacement therapy

Nephrologie et Therapeutique

Volumn 2, Issue SUPPL. 2, 2006, Pages

  Desnick, Robert J ^a   Banikazemi, Maryam ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Galactosidase A; Clinical spectrum; Enzyme replacement therapy; Fabrazyme*; Fabry disease

Indexed keywords

AGALSIDASE BETA; ALPHA GALACTOSIDASE;

CONFERENCE PAPER; DIALYSIS; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; ENZYME THERAPY; EVIDENCE BASED MEDICINE; FABRY DISEASE; HUMAN; LYSOSOME STORAGE DISEASE; PALLIATIVE THERAPY; PHENOTYPE;

ALPHA-GALACTOSIDASE; CEREBROVASCULAR DISORDERS; EYE DISEASES; FABRY DISEASE; HEART DISEASES; HETEROZYGOTE DETECTION; HUMANS; KIDNEY DISEASES;

EID: 31544468107     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (76)

1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967;276:1163-7.
2. Desnick RJ, Ioannou YA, Eng CM. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Kinzler KE, Vogelstein B, editor. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill 2001; p.3733-74.
3. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002;81:122-38.
4. Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, Obrador GT. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002;61:249-55.
5. Colombi A, Kostyal A, Bracher R, Gloor F, Mazzi R, Tholen H. Angiokeratoma corporis diffusum-Fabry's disease. Helv Med Acta 1967;34:67-83.
6. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-60.
7. Elleder M, Bradova V, Smid F, Budesinsky M, Harzer K, Kustermann-Kuhn B, Ledvinova J, Belohlavek, Krai V, Dorazilova V. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990;417:449-55.
8. von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, Desnick RJ. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991;324:395-9.
9. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H, Tanaka H. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-93.
10. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez ALD, Eng CE, Tanaka H, Tei C, Desnick RJ. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003;64:801-7.
11. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, Elliott PM. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002;105:1407-11.
12. Meehan SM, Junsanto T, Rydel JJ, Desnick RJ. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications. Am J Kidney Dis 2004;43:164-71.
13. Spada M, Pagliardini S. Screening for Fabry disease in end-stage nephropathies. J Inherit Metab Dis 2002;25 Suppl. 1:113.
14. Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlander T, Auinger M, Demmelbauer K, Lorenz M, Hauser AC, Kofler HJ, Lhotta K, Neyer U, Pronai W, Wallner M, Wieser C, Wiesholzer M, Zodl H, Fodinger M, Sunder-Plassmann G. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 2004;15:1323-9.
15. Rosenthal D, Lien YH, Lager D, Lai LW, Shang S, Leung N, Fervenza FC. A novel alpha-galactosidase a mutant (M42L) identified in a renal variant of Fabry disease. Am J Kidney Dis 2004;85-9.
16. Eng CM, Banikazemi M, Gordon R, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dickman S, Stacy CB, Fallon JT, Brodie S, Mehta D, Parsons R, Norton K, O'Callaghan M, Desnick RJ. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001;68:711-22.
17. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Eng J Med 2001;345:9-16.
18. Schiffmann R, Kopp JB, Austin HA, 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.
19. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004;75:65-74.
20. Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr 2004;144:520-6.
21. Dutsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ. Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 2002;19:575-86.
22. Tan SV, Lee PJ, Walters RJ, Mehta A, Bostock H. Evidence for motor axon depolarization in Fabry disease. Muscle Nerve 2005;32:448-451.
23. Clarke JT, Knaack J, Crawhall JC, Wolfe LS. Ceramide trihexosidosis (Fabry's disease) without skin lesions. N Engl J Med 1971;284:233-5.
24. Pabico RC, Atancio BC, McKenna BA, Pamukcoglu T, Yodaiken R. Renal pathologic lesions and functional alterations in a man with Fabry's disease. Am J Med 1973;55:415-25.
25. Sheth KJ, Roth DA, Adams MB. Early renal failure in Fabry's disease. Am J Kidney Dis 1983;2:651-4.
26. Sessa A, Meroni M, Battini G, Righetti M, Maglio A, Tosoni A, Nebuloni M, Vago G, Giordano F. Renal involvement in Anderson-Fabry disease. J Nephrol 2003;16:310-3.
27. Warnock DG. Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens 2005;14:87-95.
28. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-42.
29. Bass JL, Shrivastava S, Grabowski GA, Desnick RJ, Moller JH. The M-mode echocardiogram in Fabry's disease. Am Heart J 1980;100:807-12.
30. Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol 1986;7:1157-61.
31. Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M, Gal A, Beck M. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 2002;40:1668-74.
32. Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003;107:1978-84.
33. Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudova J, Karetova D, Zeman J, Ledvinova J, Poupetova H, Elleder M, Aschermann M. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000;139:1101-8.
34. Weidemann F, Breunig F, Beer M, Sandstede J, Stork S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005;26:1221-7.
35. Colucci WS, Lorell BH, Schoen FJ, Warhol MJ, Grossman W. Hypertrophic obstructive cardiomyopathy due to Fabry's disease. N Engl J Med 1982;307:926-8.
36. Altarescu G, Moore DF, Schiffmann R. Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology 2005;64:2148-50.
37. Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry's disease. Arch Ophthalmol 1979;97:671-6.
38. Orssaud C, Dufier J, Germain D. Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet 2003;24:129-39.
39. Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A. Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Experiment Ophthalmol 2005;33:164-8.
40. Galanos J, Nicholls K, Grigg L, Kiers L, Crawford A, Becker G. Clinical features of Fabry's disease in Australian patients. Intern Med J 2002;32:575-84.
41. Friedman LS, Kirkham SE, Thistlethwaite JR, Platika D, Kolodny EH, Schuffler MD. Jejunal diverticulosis with perforation as a complication of Fabry's disease. Gastroenterology 1984;86:558-63.
42. Roberts DH, Gilmore IT. Achalasia in Anderson-Fabry's disease. J R Soc Med 1984;77:430-1.
43. Field DG, Ostrov BE, Devenyi AG, Hoban TF. Achalasia in an adolescent with Fabry disease. J Pediatr Gastroenterol Nutr 2001;32:201-3.
44. Germain DP, Avan P, Chassaing A, Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of 22 consecutive hemizygous male patients. BMC Med Genet 2002;3:10-20.
45. Brown LK, Miller A, Bhuptani A, Sloane MF, Zimmerman MI, Schitero G, Eng CM, Desnick RJ. Pulmonary involvement in Fabry disease. Am J Respir Crit Care Med 1997;155:1004-10.
46. Willard HF. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Kinzler KE, Vogelstein B, editor. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill 2001; p.1191-212.
47. Morrone A, Cavicchi C, Bardelli T, Antuzzi D, Parini R, Di Rocco M, Feriozzi S, Gabrielli O, Barone R, Pistone G, Spisni C, Ricci R, Zammarchi E. Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers. J Med Genet 2003;40:e103.
48. Dobrovolny R, Dvorakova L, Ledvinova J, Magage S, Bultas J, Lubanda JC, Elleder M, Karetova D, Pavlikova M, Hrebicek M. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med 2005;83:647-54.
49. MacDermot KD, Holmes A, Miners AH. Anderson Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-75.
50. Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, Bruhl K, Gal A, Bunge S, Beck M. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001;24:715-24.
51. Desnick RJ, Simmons RL, Allen KY, Woods JE, Anderson CF, Najarian JS, Krivit W. Correction of enzymatic deficiencies by renal transplantation: Fabry's disease. Surgery 1972;72:203-11.
52. Nagao Y, Nakashima H, Fukuhara Y, Shimmoto M, Oshima A, Ikari Y, Mori Y, Sakuraba H, Suzuki Y. Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of α-gatactosidase A. Clin Genet 1991;39:233-7.
53. Utsumi K, Kase R, Takata T, Sakuraba H, Matsui N, Saito H, Nakurama T, Kawabe M, Lino Y, Katayam Y. Fabry disease in patients receiving maintenance dialysis. Clin Exp Nephrol 2000;4:49-51.
54. Desnick RJ. Fabry disease: unregonized ESRD patients and effectiveness of enzyme replacement on renal pathology and function. J Inherit Metab Dis 2002;25, Suppl. 1:116.
55. Pisani A, Spinelli L, Sabbatini M, Andreucci MV, Procaccini D, Abbaterusso C, Pasquali S, Savoldi S, Comotti C, Cianciaruso B. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis 2005;46:120-7.
56. Mapes CA, Anderson RL, Sweeley CC, Desnick RJ, Krivit W. Enzyme replacement in Fabry's disease, an inborn error of metabolism. Science 1970;169:987-9.
57. Brady RO, Tallman JF, Johnson WG, Gal AE, Leahy WR, Quirk JM, Dekaban AS. Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease. N Engl J Med 1973;289:9-14.
58. Desnick RJ, Dean KJ, Grabowski G, Bishop DF, Sweeley CC. Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic α-galactosidase A isozymes. Proc Natl Acad Sci USA 1979;76:5326-30.
59. Bishop DF, Calhoun DH, Bernstein HS, Hantzopoulos P, Quinn M, Desnick RJ. Human α-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci USA 1986;83:4859-63.
60. Ioannou YA, Bishop DF, Desnick RJ. Overexpression of human α-galactosidase A results in its intracellular aggregation, crystallization in lysosomes and selective secretion. J Cell Biol 1992;119:1137-50.
61. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. Fabry disease: preclinical studies demonstrate the effectiveness of α-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 2001;68:14-25.
62. Wang AM, Ioannou YA, Zeidner KM, Gotleb RW, Dikman S, Stewart CL, Desnick RJ. Generation of a mouse model with α-galactosidase A deficiency. Am J Hum Genet 1996;59:A208.
63. Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, Quirk JM, Zirzow GC, Borowski M, Loveday K, Anderson T, Gillespie F, Oliver KL, Jeffries NO, Doo E, Liang TJ, Kreps C, Gunter K, Frei K, Crutchfield K, Selden RF, Brady RO. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 2000;97:365-70.
64. Desnick RJ. Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval. Expert Opin Biol Ther 2004;4:1167-76.
65. Hopkin RJ, Bissler J, Grabowski GA. Comparative evaluation of alpha-galactosidase A infusions for treatment of Fabry disease. Genet Med 2003;5:144-53.
66. Lee K, Jin X, Zhang K, Copertino L, Andrews L, Baker-Malcolm J, Geagan L, Qiu H, Seiger K, Barngrover D, McPherson JM, Edmunds T. A Biochemical and Pharmacological Comparison of Enzyme Replacement Therapies for the Glycolipid Storage Disorder Fabry Disease. Glycobiology 2003;13:305-13.
67. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002;62:1933-46.
68. De Schoenmakere G, Chauveau D, Grunfeld JP. Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant 2003;18:33-5.
69. Waldek S. PR interval and the response to enzyme-replacement therapy for Fabry's disease. N Engl J Med 2003;348:1186-7.
70. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108:1299-301.
71. Spinelli L, Pisani A, Sabbatini M, Petretta M, Andreucci MV, Procaccini D, Lo Surdo N, Federico S, Cianciaruso B. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet 2004;66:158-65.
72. Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 2005;85:255-9.
73. Hilz MJ, Brys M, Marthol H, Stemper B, Dutsch M. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology 2004;62:1066-72.
74. Guffon N, Fouilhoux A. Clinical benefit in Fabry patients given enzyme replacement therapy-a case series. J Inherit Metab Dis 2004;27:221-7.
75. Kosch M, Koch HG, Oliveira JP, Soares C, Bianco F, Breuning F, Rasmussen AK, Schaefer RM. Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease. Kidney Int 2004;66:1279-82.
76. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338-46.